Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytoDyn Inc.
Report date January 10, 2019 · Filed January 10, 2019
Section 16 reporting ended · disclosed 2019-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2019-05-29 | Direct | 0 |
Reported balance
After 2019-01-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-10 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2024-05-29 | Direct | 100,000 |
Reported balance
After 2019-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-10 · Grant · Acquired 100,000 · Balance 100,000 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2019-06-01 | Direct | 0 |
Reported balance
After 2019-01-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-10 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2024-06-01 | Direct | 50,000 |
Reported balance
After 2019-01-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-10 · Grant · Acquired 50,000 · Balance 50,000 F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2: Such options were fully vested and exercisable as of the date of the reported transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions.
F2: Such options were fully vested and exercisable as of the date of the reported transactions.
GILEAD SCIENCES, INC.
Report date May 08, 2007 · Filed May 15, 2007
Section 16 reporting ended · disclosed 2007-05-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2019 Filed Jan 10, 2019 22:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-19-000988 · doc4.xml · derivative · entry 4 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2024-06-01 F1 · kind: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F1 · price: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| January 10, 2019 Filed Jan 10, 2019 22:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-19-000988 · doc4.xml · derivative · entry 3 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · kind: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F1 · price: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| January 10, 2019 Filed Jan 10, 2019 22:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0000899243-19-000988 · doc4.xml · derivative · entry 2 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-05-29 F1 · kind: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F1 · price: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| January 10, 2019 Filed Jan 10, 2019 22:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0000899243-19-000988 · doc4.xml · derivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2019-05-29 F1 · kind: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F1 · price: The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. F2 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 200,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 19 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Group LLC Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2022-11-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 666,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 18 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 0 Underlying: Common Stock · 666,666 shares Expires 2022-05-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerWarrants (right to buy) · Derivative | 1,333,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 17 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 0 Underlying: Common Stock · 1,333,334 shares Expires 2023-01-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 950,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 16 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 950,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F6 · derivative.exercise_date: The options vest in equal monthly installments over the two-year period commencing on July 8, 2018. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 15 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 128,530 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 14 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,530 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 450,000 | Not disclosed Strike: $0.76 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 13 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2027-02-12 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F5 · derivative.exercise_date: The options vest upon the achievement of certain strategic milestones specified in the award agreement. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 550,000 | Not disclosed Strike: $0.76 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 12 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 550,000 shares Expires 2027-02-12 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F4 · derivative.exercise_date: The options vest in equal monthly installments over the two-year period commencing on March 12, 2017. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 11 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 250,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 10 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2025-06-11 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 9 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 8 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 11,543 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 7 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,543 shares Expires 2022-05-21 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 6 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · derivative · entry 5 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2019-05-29 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 62,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · nonDerivative · entry 4 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 26,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · nonDerivative · entry 3 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · nonDerivative · entry 2 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Group LLC Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:26 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 2,093,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029186 · doc4.xml · nonDerivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 200,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 20 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Group LLC Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-11-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 333,333 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 19 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 333,333 Underlying: Common Stock · 333,333 shares Expires 2022-05-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 333,333 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 18 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 333,333 Underlying: Common Stock · 333,333 shares Expires 2022-05-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 1,333,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 17 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 1,333,334 Underlying: Common Stock · 1,333,334 shares Expires 2023-01-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 950,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 16 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F6 · derivative.exercise_date: The options vest in equal monthly installments over the two-year period commencing on July 8, 2018. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 15 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 128,530 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 14 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,530 Underlying: Common Stock · 128,530 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 450,000 | Not disclosed Strike: $0.76 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 13 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-02-12 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F5 · derivative.exercise_date: The options (including predecessor options) vest upon the achievement of certain strategic milestones specified in the award agreement. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 550,000 | Not disclosed Strike: $0.76 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 12 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2027-02-12 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F4 · derivative.exercise_date: The options (including predecessor options) vest in equal monthly installments over the two-year period commencing on March 12, 2017. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 11 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 250,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 10 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2025-06-11 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 9 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 8 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 11,543 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 7 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,543 Underlying: Common Stock · 11,543 shares Expires 2022-05-21 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 6 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · derivative · entry 5 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2019-05-29 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 62,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · nonDerivative · entry 4 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,136 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 26,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · nonDerivative · entry 3 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 26,000 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · nonDerivative · entry 2 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Group LLC Disclosed balance after: 200,000 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · ownership.nature: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 2,093,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029254 · doc4.xml · nonDerivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 2,093,972 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:58 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 950,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000899243-18-016233 · doc4.xml · derivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options will vest in equal monthly installments over the next two years, commencing on the first month following the grant date. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000899243-18-004433 · doc4.xml · derivative · entry 2 Caracciolo Anthony · CIK 0001258929 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2023-06-01 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000899243-18-004433 · doc4.xml · derivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2018-06-01 F1 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 128,530 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-003451 · doc4.xml · derivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,530 Underlying: Common Stock · 128,530 shares Expires 2028-02-07 F1 · price: On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model. Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 01:18 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 1,333,334 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-002767 · doc4.xml · derivative · entry 5 Caracciolo Anthony · CIK 0001258929 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 1,333,334 Underlying: Common Stock · 1,333,334 shares Expires 2023-01-31 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants. Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 01:18 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 2,093,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002767 · doc4.xml · nonDerivative · entry 1 Caracciolo Anthony · CIK 0001258929 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 2,093,972 F1 · price: The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants. Read SEC document |
| January 31, 2018 Filed Sep 7, 2018 22:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrants (right to buy) · Derivative | 666,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-024032 · doc4.xml · derivative · entry 2 Caracciolo Anthony · CIK 0001258929 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Caracciolo Family Trust Disclosed balance after: 666,666 Underlying: Common Stock · 666,666 shares Expires 2022-05-31 F1 · price: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the "old" warrant and the acquisition of a new one. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.